Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Pfizer/NextWave, Genzyme/Alnylam, AstraZeneca/Ironwood

Executive Summary

Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.

You may also be interested in...



Abbott Ups Its Ante On ADCs With Expanded Seattle Genetics Deal

Abbott broadens its deal with Seattle Genetics in the hot space of antibody-drug conjugates just days after announcing a pipeline setback with another partner.

Genzyme’s Asian Expertise Drives Alnylam Co-Development Pact For TTR Candidates

RNAi pioneer Alnylam is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.

Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets

Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel